Concord Biotech Ltd.
Research Concord Biotech Ltd. (CONCORDBIO.NS) on Bullrun: market cap INR 140.08B, P/E 45.9, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCONCORDBIO.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyINR
- Market capINR 140.08B
- P/E45.9
- Dividend yield0.6%
- Financial periodQ2 2026
- RevenueINR 2.57B
- Net incomeINR 576.97M
- Gross margin78.9%
Valuation Snapshot
latest market cap is INR 140.08B; P/E is 45.9; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 45.89x versus a Healthcare sector median of 21.74x (111.0% above).
Latest dividend yield is 0.56% versus a Healthcare sector median of 2.4% (76.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 140.08B | 45.9 | 0.6% | 7.55 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 7.55 INR, yield 0.6%.
About Concord Biotech Ltd.
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Concord Biotech Ltd.'s market cap?
Concord Biotech Ltd.'s market capitalization is INR 140.08B.
What is Concord Biotech Ltd.'s P/E ratio?
Concord Biotech Ltd.'s price-to-earnings (P/E) ratio is 45.9.
Does Concord Biotech Ltd. pay a dividend?
Concord Biotech Ltd. has a dividend yield of 0.6%.
What does Concord Biotech Ltd. do?
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas.